白塞病(Behcet's disease,BD)是一种以复发性口腔溃疡为首发、逐渐伴发外阴溃疡、结节性红斑等皮肤黏膜病变为基本临床特征,可能选择性发生眼炎、肠溃疡、主动脉瓣反流、静脉血栓、动脉狭窄、动脉瘤、关节炎或血细胞减少症等1~2个寡器官损害的变异性血管炎。在“丝绸之路”沿线国家的发病率较高,其中东亚的发病率为(13.5~20)/100 000[1]。骨髓增生异常综合征(myelodysplastic syndromes,MDS)是一种以骨髓造血细胞异常导致外周血细胞减少的血液系统疾病[2],8号染色体三体是MDS中最常见的一种染色体数目异常。目前国内关于BD合并8号染色体三体的报道尚不多见,其发病机制及临床特点亦不明确。本文总结复旦大学附属华东医院风湿科收治的22例BD合并8号染色体三体患者,与1 236例不合并8号染色体三体的BD患者进行比较,并检索中英文文献库,筛选8号染色体三体BD患者46例,对比分析其临床特点,探讨8号染色体三体异常与BD临床特点的相关性,提高临床医师对该类疾病的关注。
资料和方法研究对象 收集2012年10月至2020年7月在复旦大学附属华东医院风湿免疫科住院的BD患者1 258例,对存在一系或多系血细胞异常的患者进行骨髓穿刺,筛选出8号染色体三体的病例,共计22例,分析其临床特点并随访。并通过文献库检索,总结8号染色体三体的BD患者46例。所有病例均符合2013年BD国际诊断标准(international criteria for Behcet's disease,ICBD),根据患者的症状和体征进行评分,所有患者得分均≥4分[3]。通过骨髓染色体及FISH检查明确8号染色体三体。本研究得到复旦大学附属华东医院伦理委员会批准(批准号:2018K003),入选者均签署知情同意书。
研究方法 以“白塞病”与“8号染色体三体”为检索词,检索万方、维普、中国知网数据库,以“Behcet′s disease”与“trisomy 8”为检索词在PubMed中进行检索,筛选出8号染色体三体的病例。与本研究中22例8号染色体三体的病例汇总,记录每一病例的性别、年龄、发病年龄、病程、包括并发症在内的所有临床表现,并进行对比分析。
统计学处理 采用SPSS 19.0软件进行统计学分析。计量资料以x±s表示,采用t检验;计数资料采用χ2检验。P < 0.05为差异有统计学意义。
结果一般资料 22例BD合并8号染色体三体的患者中,男性5例,女性17例;平均发病年龄(45.6±11.4)岁;文献库检索到的46例患者中,男性22例,女性24例,平均发病年龄为(49.6±18.3)岁。
临床表现 22例患者均存在口腔溃疡;19例患者有外阴溃疡(86.4%);14例患者有皮疹(63.6%),主要以结节性红斑、毛囊炎及脓疱疹为主;8例患者针刺反应阳性(46.4%);6例患者存在关节肿痛,并经关节超声检查证实有关节炎(27.3%),以单侧膝关节、肘关节为主;22例患者均出现骨髓细胞形态学的异常,5例表现符合MDS(22.7%);15例患者存在肠溃疡(68.2%),其中1例患者因腹痛就诊发现溃疡穿孔行手术治疗,术后出现肠梗阻行二次手术,其余患者均无明显腹痛、腹泻、便血等症状;1例患者头颅MRI发现左侧小脑半球异常信号灶(约20 mm×15 mm),病灶周围水肿,可能为低级别胶质瘤,无神经系统症状。所有患者外周血管B超、心超均未见异常。我科收住的22例BD合并8号染色体三体的患者与文献库中检索到的46例患者相比较,仅合并MDS的比例不同(P=0.000),其余表现均相符(表 1)。与不合并8号染色体三体的1 236例BD患者比较,合并8号染色体三体的患者女性占多数(P=0.040),眼睛损害少见(P=0.033),肠溃疡多发(P < 0.001)以及更易合并MDS(P < 0.001),两组患者的口腔溃疡、外阴溃疡、关节炎、皮肤损害、神经系统病变、血管病变以及心脏病变均无显著差异(表 2)。
[(x±s) or n(%)] | |||||||||||||||||||||||||||||
Characteristics | BD with trisomy 8 (our group,n=22) | BD with trisomy 8 (in literature,n=46) | t or χ2 | P | |||||||||||||||||||||||||
Age at BD diagnosis (y) | 45.6±11.4 | 49.6 ± 18.3 | -0.621 | 0.968 | |||||||||||||||||||||||||
Male/Female | 5/17 | 22/24 | 3.916 | 0.063 | |||||||||||||||||||||||||
Oral ulcer | 22 (100) | 46 (100) | - | - | |||||||||||||||||||||||||
Genital ulcer | 19 (86.4) | 37 (80.4) | 0.360 | 0.498 | |||||||||||||||||||||||||
Ocular lesion | 0 (0) | 3 (6.5) | 1.501 | 0.546 | |||||||||||||||||||||||||
Skin lesions | 14 (63.6) | 27 (58.7) | 0.152 | 0.595 | |||||||||||||||||||||||||
Positive pathergy test | 8 (46.4) | 22 (47.8) | 0.793 | 0.373 | |||||||||||||||||||||||||
Arthritis | 6 (27.3) | 10 (21.7) | 0.253 | 0.685 | |||||||||||||||||||||||||
Central nervous system | 1 (4.5) | 0 (0) | 2.122 | 0.154 | |||||||||||||||||||||||||
Vascular lesions | 0 (0) | 6 (13) | 3.147 | 0.166 | |||||||||||||||||||||||||
Cardiac involvement | 0 (0) | 0 (0) | - | - | |||||||||||||||||||||||||
Intestinal ulcers | 15 (68.2) | 36 (78.3) | 0.806 | 0.552 | |||||||||||||||||||||||||
Abnormal morphology of bone marrow cells | 22(100) | 46 (100) | - | - | |||||||||||||||||||||||||
MDS | 5 (22.7) | 44 (100) | 35.770 | < 0.001 |
[n(%)] | |||||||||||||||||||||||||||||
Characteristics | BD with trisomy 8 (n=22) | BD with trisomy 8 (n=1 236) | χ2 | P | |||||||||||||||||||||||||
Male/Female | 5/17 | 667/569 | 8.476 | 0.040 | |||||||||||||||||||||||||
Oral ulcer | 22 (100) | 1147 (91.0) | 1.705 | 0.192 | |||||||||||||||||||||||||
Genital ulcer | 19 (86.4) | 850 (67.2) | 3.132 | 0.077 | |||||||||||||||||||||||||
Ocular lesion | 0 (0) | 179 (14.5) | 3.715 | 0.033 | |||||||||||||||||||||||||
Skin lesions | 14(63.6) | 637 (50.4) | 1.267 | 0.260 | |||||||||||||||||||||||||
Arthritis | 6 (27.3) | 245(19.3) | 0.751 | 0.386 | |||||||||||||||||||||||||
Central nervous system | 1 (4.5) | 35 (2.8) | 0.228 | 0.633 | |||||||||||||||||||||||||
Vascular lesions | 0 (0) | 69 (5.6) | 1.299 | 0.254 | |||||||||||||||||||||||||
Cardiac involvement | 0 (0) | 41 (3.3) | 0.754 | 0.385 | |||||||||||||||||||||||||
Intestinal ulcers | 15 (68.2) | 160 (12.9) | 55.070 | < 0.001 | |||||||||||||||||||||||||
MDS | 5 (22.7) | 15 (1.2) | 63.944 | < 0.001 |
实验室指标 22例患者均出现1系或多系血细胞减少,其中16例外周血白细胞减少,17例外周血血红蛋白减少,14例外周血血小板减少。对22例患者实验室指标进行统计,WBC为(3.3±1.9)×109/L;Hb为(102.5±16.9) g/L;PLT为(121.1±92.5)×109/L;炎症指标明显升高[ESR为(45.2±35.2)mm/h,CRP为(24.5±32.6)mg/L,SAA为(77.2±87.7) mg/L,IL-6为(23.5±49.1)pg/mL,铁蛋白为(267.9±264.3)ng/mL];谷丙转氨酶及肌酐均无明显异常[ALT为(19.2±12.1)U/L;Cr为(57.6±16.9) μmol/L];3例T-SPOT阳性;ANA均为阴性。22例患者均有染色体异常,1例骨髓染色体检查为49,XX,+7,+8,+15[6]/48,XX,+7,+8[4],1例49,XY,+8,+9,其余20例均为47,XX,+8/47,XY,+8;FISH检查均显示Vysis CEP8阳性(+8)。
22例患者均出现不同程度的骨髓细胞形态学的异常,5例表现符合MDS(22.7%),其余17例多次复查骨穿结果呈现变化,有向MDS进展的趋势。合并或不合并MDS的患者临床指标比较,血红蛋白有显著差异(P < 0.05),发病年龄、性别、肠溃疡、白细胞、血小板、ESR、CRP等均无明显差异(表 3)。
[(x±s) or n(%)] | |||||||||||||||||||||||||||||
Characteristics | BD-trisomy 8 with MDS (n=5) | BD-trisomy 8 without MDS (n=17) | t or χ2 | P | |||||||||||||||||||||||||
Age at BD diagnosis (years) | 51.8±11.6 | 43.8±11.1 | -1.413 | 0.173 | |||||||||||||||||||||||||
Male/Female | 1/4 | 4/13 | 0.027 | 0.687 | |||||||||||||||||||||||||
Intestinal ulcers | 5 (100) | 10 (58.8) | 3.020 | 0.082 | |||||||||||||||||||||||||
WBC (109/L) | 3.9±2.2 | 3.1±1.8 | -0.736 | 0.470 | |||||||||||||||||||||||||
Hemoglobin (g/L) | 87.4±12.9 | 107.0±15.4 | 2.573 | 0.018 | |||||||||||||||||||||||||
Platelets (109/L) | 73.4±44.0 | 44.0±99.1 | 1.336 | 0.197 | |||||||||||||||||||||||||
ESR (mm/h) | 69.0±38.2 | 38.2±30.1 | -1.811 | 0.085 | |||||||||||||||||||||||||
CRP (mg/L) | 34.4±46.2 | 21.6±28.7 | -0.766 | 0.453 | |||||||||||||||||||||||||
WBC:White blood cell;ESR:Erythrocyte sedimentation;CRP:C-reactive protein. |
治疗及随访 15例合并肠溃疡的患者予以沙利度胺、环孢素、激素以及英夫利昔单抗治疗,1例患者用药过程中出现严重肺部感染,停用英夫利昔单抗,继续口服药物治疗;1例患者出院后未再就诊;6例患者口服沙利度胺、环孢素及激素治疗。至2020年7月,18例患者病情稳定继续治疗随访中,3例患者因出血或肺部感染死亡,1例患者失访。
讨论BD是一种可累及全身多个器官的慢性炎性疾病,1937年土耳其皮肤科医师Behcet’s首次报道[4]。目前尚无特异性血清指标,主要依据临床症状进行诊断。MDS是一种恶性克隆性疾病,由造血干、祖细胞发育异常所引起,8号染色体三体是MDS中最常见的一种染色体数目异常。研究发现8号三体与骨髓原始细胞危象、嗜酸细胞增多症的发生有着密切联系[5]。根据国际预后指数修改版(IPSS-R)标准,8号染色体三体被归为MDS的细胞遗传危险因素[6]。有研究[7]显示8号染色体三体的形成可能与NQO1酶缺陷相关。8号染色体三体BD合并MDS的报道多分布于韩国和日本[8-10],国内相关报道相对较少,本文拟阐述BD合并8号染色体三体患者的临床特点,提高临床医师对其认识。
本文22例8号染色体三体BD患者MDS的发生率为22.7%,其余患者目前虽尚不能诊断为MDS,但均出现不同程度的骨髓造血异常,存在发展为MDS的可能,需长期随访。8号染色体三体异常可能是BD患者并发MDS的高危因素。根据已有的22例患者并结合相关文献检索可发现,8号染色体三体的BD患者更易合并MDS,更易累及肠道,而眼睛、心脏、血管、神经系统、关节很少累及[11-12]。既往文献表明,BD合并MDS患者肠道损害的发生率(77.3%)明显高于单纯BD患者(15.5%)[9, 13]。本研究小组曾对2013年10月至2015年10月住院确诊为BD的375例患者进行分析统计,存在消化道损害的患者有44例(11.7%)[14],而本次统计的不合并8号染色体三体的BD患者中,肠溃疡的患者有160例(12.9%),22例8号染色体三体异常的BD患者的消化道损害的发生率明显升高(68.2%),这一结果也与既往文献报道相符[15-18]。
8号染色体三体与BD患者出现肠道累及有一定联系,但其机制尚不清楚。有文献对具有8号染色体三体异常的MDS患者进行研究分析,发现部分细胞因子的表达明显升高,包括转化生长因子-β,干扰素-β2、IL-6和IL-7R等,而这些因子都参与了免疫和炎症活动[19]。BD是一种慢性炎性疾病,存在多种细胞因子的异常,包括IL-1β、IL-6、IL-8、IL-17和TNF-α等[20]。BD合并8号染色体三体患者的血清中存在特殊的细胞因子,血清中细胞因子G-CSF、IL-6、IL-8、TNF-α均明显升高[21]。8号染色体上存在多种基因,如IL-7、小诱导因子A5(RANTES)、TNF受体超家族等[22],这些基因编码的炎性因子的过度表达可能与BD的发病相关。可以推测BD和8号染色体三体可能起源于同一免疫异常,造成骨髓造血干细胞破坏导致MDS,引起其他组织和器官的损害。
目前对于BD合并8号染色体三体异常患者尚无特效治疗方法,考虑到炎症因子在其中发挥一定作用,通常在常规BD治疗基础上调整剂量或合用生物制剂[19-20, 23-25]。在BD合并MDS、8号染色体三体异常的患者中,肠道损害是较常见的症状,病情重且治疗困难[26-27]。对于出现肠道累及的患者,可在增加常规药物剂量的基础上,延长生物制剂使用时间,预后方面个体差异性大。
综上所述,8号染色体三体的BD合并肠溃疡可能是一种新的综合征,目前致病机制不明,可能是后天基因突变引起的自身炎症性疾病,其诊断、治疗及预后均有别于典型的BD或MDS。BD患者出现一系或多系血细胞异常时,及时进行骨髓细胞形态学、染色体以及FISH检查,有助于早期诊断MDS。对于8号染色体三体异常的BD患者,即使没有消化道症状,也应及早进行肠镜检查以明确消化道病变,对减少消化道溃疡出血、穿孔等并发症的发生有重要意义。
作者贡献声明 马海芬,申艳 数据采集,论文构思、撰写和修订。罗丹,蔡剑飞 数据采集。邹峻,管剑龙 论文修订。
利益冲突声明 所有作者均声明不存在利益冲突。
[1] |
ZOUBOULIS CC, KOTTER I, DJAWARI D, et al. Epidemiological features of Adamantiades-Behcet's disease in Germany and in Europe[J]. Yonsei Med J, 1997, 38(6): 411-422.
[DOI]
|
[2] |
GARCIA-MANERO G. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management[J]. Am J Hematol, 2014, 89(1): 97-108.
[DOI]
|
[3] |
The International Criteria for Behcet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria[J]. J Eur Acad Dermatol Venereol, 2014, 28(3): 338-347.
|
[4] |
SAKANE T, TAKENO M, SUZUKI N, et al. Behcet's disease[J]. N Engl J Med, 1999, 341(17): 1284-1291.
[DOI]
|
[5] |
PITCHFORD CW, HETTINGA AC, REICHARD KK. Fluorescence in situ hybridization testing for -5/5q, -7/7q, +8, and del(20q) in primary myelodysplastic syndrome correlates with conventional cytogenetics in the setting of an adequate study[J]. Am J Clin Pathol, 2010, 133(2): 260-264.
[DOI]
|
[6] |
CALVO X, ARENILAS L, LUNO E, et al. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R)[J]. Am J Hematol, 2017, 92(7): 614-621.
[DOI]
|
[7] |
KING RW. When 2+2=5:the origins and fates of aneuploid and tetraploid cells[J]. Biochim Biophys Acta, 2008, 1786(1): 4-14.
[URI]
|
[8] |
KAWANO S, HIRAOKA S, OKADA H, et al. Clinical features of intestinal behcet's disease associated with myelodysplastic syndrome and trisomy 8[J]. Acta Med Okayama, 2015, 69(6): 365-369.
[PubMed]
|
[9] |
ESATOGLU SN, HATEMI G, SALIHOGLU A, et al. A reappraisal of the association between Behcet's disease, myelodysplastic syndrome and the presence of trisomy 8:a systematic literature review[J]. Clin Exp Rheumatol, 2015, 33(6 Suppl 94): S145-S151.
[URI]
|
[10] |
KIMURA M, TSUJI Y, IWAI M, et al. Usefulness of adalimumab for treating a case of intestinal Behcet's disease with trisomy 8 myelodysplastic syndrome[J]. Intest Res, 2015, 13(2): 166-169.
[DOI]
|
[11] |
KOGUCCHI-YOSHIOKA H, INOKUMA D, KANDA M, et al. Behcet's disease-like symptoms associated with myelodysplastic syndrome with trisomy 8:a case report and review of the literature[J]. Acta Derm Venereol, 2014, 94(3): 355-356.
[DOI]
|
[12] |
SHEN Y, MA HF, LUO D, et al. High incidence of gastrointestinal ulceration and cytogenetic aberration of trisomy 8 as typical features of Behcet's disease associated with myelodysplastic syndrome: a series of 16 consecutive Chinese patients from the Shanghai Behcet's Disease database and comparison with the literature[J]. Biomed Res Int, 2018, 2018: 8535091.
[URI]
|
[13] |
TADA Y, KOARADA S, HARUTA Y, et al. The association of Behcet's disease with myelodysplastic syndrome in Japan: a review of the literature[J]. Clin Exp Rheumatol, 2006, 24(5 Suppl 42): S115-S119.
|
[14] |
申艳, 罗丹, 鲍华芳, 等. 白塞病375例临床特点及其不同性别的临床异质性研究[J]. 内科理论与实践, 2016, 11(6): 366-370. [CNKI]
|
[15] |
NARAZAKI T, SHIRATSUCHI M, TSUDA M, et al. Intestinal Behçet's disease with primary myelofibrosis involving trisomy 8[J]. Acta Haematol, 2019, 142(4): 253-256.
[DOI]
|
[16] |
WESNER N, DREVON L, GUEDON A, et al. Gastrointestinal Behcet's-like disease with myelodysplastic neoplasms with trisomy 8:a French case series and literature review[J]. Leuk Lymphoma, 2019, 60(7): 1782-1788.
[DOI]
|
[17] |
WESNER N, DREVON L, GUEDON A, et al. Inflammatory disorders associated with trisomy 8-myelodysplastic syndromes: French retrospective case-control study[J]. Eur J Haematol, 2019, 102(1): 63-69.
[DOI]
|
[18] |
ASANO T, SATO S, FURUVA MY, et al. Intestinal Behçet disease associated with myelodysplastic syndrome accompanying trisomy 8 successfully treated with abdominal surgery followed by hematopoietic stem cell transplantation: A case report[J]. Medicine (Baltimore), 2019, 98(46): e17979.
[DOI]
|
[19] |
CHEN G, ZENG W, MIYAZATO A, et al. Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities[J]. Blood, 2004, 104(13): 4210-4218.
[DOI]
|
[20] |
HAMZAOUI K, HAMZAOUI A, GUEMIRA F, et al. Cytokine profile in Behcet's disease patients.Relationship with disease activity[J]. Scand J Rheumatol, 2002, 31(4): 205-210.
[DOI]
|
[21] |
OHNO E, OHTSUKA E, WATANABE K, et al. Behçet's disease associated with myelodysplastic syndromes.A case report and a review of the literature[J]. Cancer, 1997, 79(2): 262-268.
[DOI]
|
[22] |
HEMSING AL, HOVLAND R, TSYKUNOVA G, et al. Trisomy 8 in acute myeloid leukemia[J]. Expert Rev Hematol, 2019, 12(11): 947-958.
[DOI]
|
[23] |
SLOAND EM, BARRETT AJ. Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success[J]. Hematol Oncol Clin North Am, 2010, 24(2): 331-341.
[DOI]
|
[24] |
MANTZOURANI MG, CHANTZIARA K, THANOPOULOU I, et al. Coexistence of Behcet's disease and chronic myelomonocyte leukemia with trisomy 8:a case report and review of the literature[J]. Clin Exp Rheumatol, 2009, 27(2 Suppl 53): S85-S87.
[URI]
|
[25] |
TANAKA N, SAKURABA H, HIRAGA H, et al. Long-term maintenance of the mucosal healing induced by azacitidine therapy in a patient with intestinal Behçet's-like disease accompanied with myelodysplastic syndrome involving trisomy 8[J]. Immunol Med, 2019, 42(3): 135-141.
[DOI]
|
[26] |
SOYSAL T, SALIHOGLU A, ESATOGLU SN, et al. Bone marrow transplantation for Behcet's disease: a case report and systematic review of the literature[J]. Rheumatology (Oxford), 2014, 53(6): 1136-1141.
[DOI]
|
[27] |
TOYONAGA T, NAKASE H, MATSUURA M, et al. Refractoriness of intestinal Behcet's disease with myelodysplastic syndrome involving trisomy 8 to medical therapies - our case experience and review of the literature[J]. Digestion, 2013, 88(4): 217-221.
[DOI]
|